HSK39297 tablets for active lupus nephritis
Part of Immune system & allergy, Kidney & urinary, Skin, Women’s health & pregnancy clinical trials.
This study tests a new drug called HSK39297 combined with standard treatments (steroids and mycophenolate mofetil) for people with active lupus nephritis. It aims to see if the combination is safe and effective in reducing kidney inflammation.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 to 75 years old.
- You have a confirmed diagnosis of active lupus nephritis (type III or IV, with or without type V) from a kidney biopsy within the last 12 months.
- You have significant protein in your urine (at least 1 gram per gram of creatinine) and a lupus disease activity score of 8 or more.
- You have not failed treatment with mycophenolate mofetil (MMF) in the past and are not allergic to MMF or steroids.
- You are willing to avoid pregnancy or donating sperm for the study period and for 30 to 90 days after the last dose.
- You do not have severe kidney failure, active infections like tuberculosis, or other major organ diseases.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called HLX79 (a human sialidase fusion protein) combined with rituximab, compared to a placebo, for people with active membranous nephropathy (a kidney disease). It aims to see if this combination can reduce protein in the urine and improve kidney function.
This trial tests a new treatment for people with lupus nephritis, a type of kidney disease caused by lupus. It may help reduce kidney inflammation and protect kidney function.
This trial tests a new medication called MSC303, given as a shot under the skin, for people with two kinds of immune-related kidney diseases. The goal is to see if it can help control the disease and improve kidney function.
This trial tests a new drug called HB2198 to see if it can help people with moderate to severe lupus. It may be an option for those whose current treatments haven't worked well enough.
This trial tests a new kind of treatment called CRC01, which uses your own immune cells modified to attack and calm the overactive immune system that causes lupus. It's for people with severe lupus that affects the kidneys and hasn't improved with standard therapies, and it aims to reduce disease activity and prevent further damage.
This trial tests a new medicine called QLG1074 added to standard treatments for people with active lupus nephritis, a kidney problem caused by lupus. It aims to see if the combination helps control the disease better.
Hear when a new Lupus Nephritis (LN) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.